NEW YORK (TheStreet) -- Pfizer (PFE - Get Report) dipped Tuesday after AstraZeneca (AZN) detailed its plan to increase sales in the next decade as an independent company as Pfizer continues to pursue a takeover of the British company.
AstraZeneca said in a statement investors would benefit from a "strong and consistent revenue growth" as annual sales would increase to more than $45 billion by 2023. The company posted sales of $25.7 billion last year.
The British company again rebuffed Pfizer's takeover bid on Friday. Pfizer's third offer was for approximately $106 billion, but the No.8 drugmaker called this offer inadequate and said a buyout would disturb its new drugs in development.
Must Read: Warren Buffett's 10 Favorite Growth Stocks
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts